Global drug giant boosts Boulder biotech's funding round to $150 million
The company's molecular research and drug-development platform taps what it calls nature's wisdom to drive the discovery of ...
Enveda Gains Backing from Sanofi to Advance AI-Driven Drug Discovery to Clinical Trials Bringing Total Series C Financing to $150M
Sanofi invests in Enveda, reaffirming the industry’s confidence in its AI drug discovery platform and ability to deliver differentiated medicines.
Nature1y
Unlocking the natural world to search for new medicines
While many drug companies avoid targets deemed ‘undruggable’, US-based Enveda Biosciences attacks them head on. Founded in 2019, Enveda uses unique libraries and machine-learning technologies ...
Yahoo Finance23d
Enveda Expands into Asthma with First-in-Class Lead Asset ENV-294 and Assembles World-Class Advisory Board
Enveda has since identified asthma as a high-impact follow-on indication for ENV-294 following promising preclinical and translational data in asthma models. This expansion underscores the company ...
Morningstar1mon
Enveda Welcomes Jason Kim as Chief Financial Officer
Enveda, a biotechnology company using AI to translate life’s chemistry into new medicines, today announced the appointment of Jason Kim as Chief Financial Officer (CFO). Mr. Kim brings more than ...
Business Insider1mon
Sanofi’s Promising Future: Buy Rating Backed by Strategic Moves and Strong Pipeline
Sanofi (SNYNF – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst David Risinger from Leerink Partners reiterated a Buy rating on the ...
Joplin Globe23d
Enveda Expands into Asthma with First-in-Class Lead Asset ENV-294 and Assembles World-Class Advisory Board
Enveda, a biotechnology company using AI to translate nature into new medicines, is proud to announce testing of its lead asset, ENV-294, in a second indication: asthma. This novel therapeutic ...